(Total Views: 532)
Posted On: 04/16/2024 7:31:03 PM
Post# of 151793
Cullinan Oncology...now known as Cullinan Therapeutics grabs $280 Million to join Lupus space in cancer...hence furthering the Autoimmune craze...shares up about 15%.
_______________________________________________________________
ABBvie inks deal for Medincell's Long-acting Platform/Technology worth up to $1.9 Billion for the development of up to six therapeutic Long-acting products.
In true form and holding their cards to their chest saying only..."Multiple therapeutic areas and indications"...ABBvie declined to comment as well. From what I have gathered the indication is likely in the area of Schizophrenia in terms of compliance.
The consistent play around the price of shares...does little for my own fragmented state of mind.....where are the assays?
_______________________________________________________________
ABBvie inks deal for Medincell's Long-acting Platform/Technology worth up to $1.9 Billion for the development of up to six therapeutic Long-acting products.
In true form and holding their cards to their chest saying only..."Multiple therapeutic areas and indications"...ABBvie declined to comment as well. From what I have gathered the indication is likely in the area of Schizophrenia in terms of compliance.
The consistent play around the price of shares...does little for my own fragmented state of mind.....where are the assays?
(1)
(0)Scroll down for more posts ▼
